Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

EC approves Zealand Pharma’s Zeydovio (glepaglutide) for short bowel syndrome – Zealand Pharma

Written by | 19 Nov 2026 | Drug Approvals

Zealand Pharma A/S announced that the European Commission (EC) has granted marketing authorization for Zeydovio (glepaglutide), a long-acting, next-generation GLP-2 analog, for the treatment of adults with short bowel syndrome (SBS).

“The European Commission’s approval of Zeydovio is an important milestone for people living with short bowel syndrome in Europe, and the first major advancement in treatment in more than a decade. Zeydovio combines proven efficacy with simple twice-weekly dosing, and it has the potential to meaningfully ease the burden of this disease.” – Adam Steensberg, President and Chief Executive Officer of Zealand Pharma.

“With this regulatory approval, our focus now turns to finding the right partner to bring Zeydovio to as many people living with short bowel syndrome as possible across Europe and beyond, and to further advance the ongoing Phase 3 EASE-5 trial to support U.S. registration.”

In the pivotal Phase 3 EASE-1 trial, twice-weekly glepaglutide delivered a statistically significant and superior reduction in parenteral support requirements versus placebo in people with SBS and intestinal failure (IF), forming the foundation of the approval. Interim data from the EASE-2 and EASE-3 extension trials, which follow patients for up to two years, and the mechanistic EASE-4 trial, which showed improved intestinal absorption with glepaglutide, strengthened the evidence. Across the clinical program to date, glepaglutide has appeared safe and well tolerated. Results from EASE-2 and EASE-3, which confirmed long-term efficacy and safety, are expected to be presented at scientific meetings in 2027.

The marketing authorization is valid in all member states of the European Union, as well as Iceland, Liechtenstein, and Norway.

Zealand Pharma is actively engaging in partnership discussions for the future global commercialization of glepaglutide for SBS.

The Phase 3 EASE-5 trial, designed to provide further confirmatory evidence to support a regulatory submission in the U.S., is ongoing, with patient recruitment progressing well.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.